RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System

NACompletedINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Carcinoma, HepatocellularLiver Neoplasms
Interventions
OTHER

Mailed Outreach Invitation

"Individuals randomized to Group 2 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."

OTHER

Mailed Outreach Invitation and Patient Navigation

"Individuals randomized to Group 3 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."

Trial Locations (1)

75235

Parkland Health & Hospital System, Dallas

All Listed Sponsors
collaborator

Agency for Healthcare Research and Quality (AHRQ)

FED

collaborator

Parkland Health and Hospital System

OTHER

collaborator

The University of Texas Health Science Center, Houston

OTHER

collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

University of Texas Southwestern Medical Center

OTHER

NCT02312817 - RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System | Biotech Hunter | Biotech Hunter